Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.

Marília Berlofa Visacri Natalia C DuarteTácio de M LimaRafael N de SouzaThiago S CobaxoJoão Cc TeixeiraCristina R BarbosaLara P DiasMariane Gr TavaresEder de C PincinatoCarmen Sp LimaPatricia Moriel

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2021)

Clinical oncology pharmacists must provide patient information on the correct use of capecitabine, manage adverse reactions, and monitor adherence to treatment. Strategies to prevent non-adherence to capecitabine must be adopted to ensure the success of pharmacotherapy.

Keyphrases

phase ii study
locally advanced
metastatic breast cancer
metastatic colorectal cancer
phase iii
papillary thyroid
glycemic control
palliative care
case report
clinical trial
squamous cell carcinoma
type diabetes
smoking cessation
health information
adipose tissue
insulin resistance
double blind